CLINICAL RESEARCH: CONGENITAL HEART DISEASE
Long-Term outcomes of cardiac pacing in adults with congenital heart disease
Fiona Walker, MD* ,
Samuel C. Siu, MD, SM, FACC*,
Shane Woods*,
Douglas A. Cameron, MD*,
Gary D. Webb, MD, FACC* and
Louise Harris, MB, ChB, FACC*,*
* Toronto Congenital Cardiac Centre for Adults, Toronto General Hospital, Toronto, Ontario, Canada
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Manuscript received August 15, 2003;
revised manuscript received December 17, 2003,
accepted December 23, 2003.
* Reprint requests and correspondence: Dr. Louise Harris, Peter Munk Cardiac Centre 3-562, Toronto General Hospital, 150 Gerrard Street West, Toronto, ON M5G 2C4, Canada.
louise.harris{at}uhn.on.ca
OBJECTIVES: The purpose of this retrospective study was to define long-term outcomes after pacemaker therapy in adults with congenital heart disease (CHD).
BACKGROUND: Adults with CHD represent a unique and expanding population. Many will require pacemaker or implantable defibrillator therapy, with a lifelong need for re-intervention and follow-up. They pose technical and management challenges not encountered in other groups receiving pacing, and the complication and re-intervention rates specific to this population are not well-defined.
METHODS: We reviewed outcomes of 168 adults with CHD, 89 females, mean age 40 years, in whom a pacemaker or anti-tachycardia device was implanted.
RESULTS: Mean age at implant was 28 years with mean pacing duration 11 years at follow-up (range, 0.5 to 38.0). Seventy-two (42%) received initial dual-chamber devices and remained in this mode, while 23 (14%) went from ventricular to dual-chamber pacing in follow-up. Initial mode of pacing did not have a significant effect on subsequent atrial arrhythmia. Patients receiving an initial epicardial system were younger than those paced endocardially (17 ± 12 years vs. 35 ± 16 years, p < 0.001) and more likely to undergo re-intervention (p = 0.019). Difficulty with vascular access was encountered in 25 patients (15%), while 45 (27%) experienced lead-related complications. No significant predictors of lead complications were identified.
CONCLUSIONS: Lead complications were not significantly different for epicardial versus endocardial, nor physiologic versus ventricular pacing, but a trend toward improved lead survival in patients receiving endocardial leads at first implant was observed. Adults with CHD remain at risk for atrial arrhythmias regardless of pacing mode.
|
Abbreviations and Acronyms
| | AT | = atrial arrhythmias | | ATD | = anti-tachycardia device therapy | | AV | = atrio-ventricular | | CHD | = congenital heart disease | | EP | = electrophysiologic | | PPM | = permanent pacemaker | | TCCCA | = Toronto Congenital Cardiac Centre for Adults |
|
This article has been cited by other articles:
|
|
|
|
 
P. Khairy, L. Harris, M. J. Landzberg, S. M. Fernandes, A. Barlow, L.-A. Mercier, S. Viswanathan, P. Chetaille, E. Gordon, A. Dore, et al.
Sudden Death and Defibrillators in Transposition of the Great Arteries With Intra-atrial Baffles: A Multicenter Study
Circ Arrhythm Electrophysiol,
October 1, 2008;
1(4):
250 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Odim, B. Suckow, B. Saedi, H. Laks, and K. Shannon
Equivalent Performance of Epicardial Versus Endocardial Permanent Pacing in Children: A Single Institution and Manufacturer Experience
Ann. Thorac. Surg.,
April 1, 2008;
85(4):
1412 - 1416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Murayama, M. Maeda, H. Sakurai, A. Usui, and Y. Ueda
Predictors affecting durability of epicardial pacemaker leads in pediatric patients.
J. Thorac. Cardiovasc. Surg.,
February 1, 2008;
135(2):
361 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Khairy, L. Harris, M. J. Landzberg, S. Viswanathan, A. Barlow, M. A. Gatzoulis, S. M. Fernandes, L. Beauchesne, J. Therrien, P. Chetaille, et al.
Implantable Cardioverter-Defibrillators in Tetralogy of Fallot
Circulation,
January 22, 2008;
117(3):
363 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Laks, D. Marelli, M. Plunkett, and J. Myers
Adult Congenital Heart Disease
Card. Surg. Adult,
January 1, 2008;
3(2008):
1431 - 1464.
[Full Text]
|
|
|
|
|
|
|
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Europace,
October 1, 2007;
9(10):
959 - 998.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Eur. Heart J.,
September 2, 2007;
28(18):
2256 - 2295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Khairy, M. J. Landzberg, M. A. Gatzoulis, L.-A. Mercier, S. M. Fernandes, J.-M. Cote, J.-P. Lavoie, A. Fournier, P. G. Guerra, A. Frogoudaki, et al.
Transvenous Pacing Leads and Systemic Thromboemboli in Patients With Intracardiac Shunts: A Multicenter Study
Circulation,
May 23, 2006;
113(20):
2391 - 2397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Janousek, V. Tomek, V. Chaloupecky, O. Reich, R. A. Gebauer, J. Kautzner, and B. Hucin
Cardiac resynchronization therapy: A novel adjunct to the treatment and prevention of systemic right ventricular failure
J. Am. Coll. Cardiol.,
November 2, 2004;
44(9):
1927 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
